SCHEMBL2365597

SCHEMBL2365597

COc1cc2c(cc1C#N)C(CI)CN(C(=O)C(F)(F)F)CC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
MTNR1B P49286 1/20 0.41
ESR1 P03372 1/20 0.40
ESR2 Q92731 1/20 0.40
MAPT P10636 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPK1 P28482 2/20 0.39
USP2 O75604 1/20 0.39
PKM P14618 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
PDE4B Q07343 1/20 0.37
PDE4D Q08499 1/20 0.37
LMNA P02545 1/20 0.37
ABCB1 P08183 1/20 0.36
DPP4 P27487 1/20 0.36
DPP8 Q6V1X1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1095169 0.85 KMT2A (0.43) KMT2AMEN1MTNR1BESR1ESR2
SCHEMBL1094747 0.76 MTNR1B (0.43) KMT2AMTNR1BESR1ESR2MAPT
SCHEMBL1096119 0.76 HTR2C (0.50) KMT2AMEN1MTNR1BESR1ESR2
SCHEMBL1095476 0.76 MTNR1B (0.43) KMT2AMEN1MTNR1BESR1ESR2
SCHEMBL1094266 0.72 HTR2A (0.48) KMT2AMTNR1BESR1ESR2KDM4E
SCHEMBL4936397 0.70 HTR2C (0.48) KMT2AMTNR1BESR1ESR2MAPK1
SCHEMBL1094406 0.70 HTR2A (0.48) KMT2AMEN1MTNR1BESR1ESR2
SCHEMBL1094838 0.70 HTR2C (0.48) KMT2AMTNR1BESR1ESR2MAPK1
SCHEMBL4936392 0.70 HTR2C (0.48) KMT2AMTNR1BESR1ESR2MAPK1
SCHEMBL21255989 0.70 ESR1 (0.69) KMT2AMEN1ESR1ESR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2363394-A1 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders Arena Pharmaceuticals, Inc. (US) 2011-09-07 EP disclosed